Revolution Medicines, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Revolution Medicines, Inc. (RVMD) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of $1.15 billion as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2026-02-25
- 2025-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $1.15B.
- 2024-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $1.15B.
- 2024-09-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $1.15B.
- 2024-06-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net $1.15B.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2025-12-31 | $1.15B 10-K · filed 2026-02-25 |
| 2024-12-31 | $1.15B 10-K · filed 2025-02-26 |
| 2024-09-30 | $1.15B 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.15B 10-Q · filed 2024-08-07 |
| 2024-03-31 | $1.15B 10-Q · filed 2024-05-08 |
| 2023-12-31 | $1.15B 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |